Table 2 Available approved drugs to target the identified GBM molecular signature and CD44 co-expression network
From: Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature
Gene | Approved drugs |
|---|---|
CD44 | Hyaluronic acid |
EGFR | Cetuximab, Gefitinib, Erlotinib, Lapatinib, Panitumumab, Lidocaine, Vandetanib, Afatinib, Necitumumab, Osimertinib, Neratinib, Brigatinib, Foreskin keratinocyte, Fostamatinib, Dacomitinib, Zanubrutinib |
C1R | Palivizumab, Conestat alfa, Human C1-esterase inhibitor |
CALR | Tenecteplase, Antihemophilic factor, Melatonin, Lonoctocog alfa, Moroctocog alfa |
TNFSR1A | Tasonermin |